

RareCyte® Inc. reports 2021 Precision Biology™ Services business and Orion™ Spatial Biology instruments growth

RareCyte Inc. a leading provider of Precision Biology products and services recognized over 100% sales growth in their 2021 Services business

SEATTLE, WA, USA, January 6, 2022 /EINPresswire.com/ -- Seattle, WA, January 6th, 2022 - [RareCyte Inc.](#), ("RareCyte" or "The Company") a leading provider of Precision Biology products and [services](#) recognized over 100% sales growth in their Services business in 2021. They also saw significant uptake by early adopters of their [Orion](#) instruments and consumables by global key opinion leaders in support of fast, subcellular whole slide spatial analysis.

The company closed new and follow-on service programs across tens of global Pharma, BioPharma, and academic customers. Key studies include programs for biomarker discovery and implementation, pharmaceutical mechanism of action, and drug safety. RareCyte's best-in-class liquid biopsy and spatial biology platforms in the full-service, CLIA-certified, laboratory were employed to provide custom assay development, research- and clinical trial- services for rare-cell liquid biopsy assays, and tissue-based spatial profiling. Clients included essential researchers, translational scientists, drug development and diagnostics organizations.

"RareCyte products and services are supported by an infrastructure that includes ISO13485 certification with a rigorous Quality Management System and CLIA Lab accreditation to support customer requirements" said Leighton Howells, Senior Vice President of Biopharma Partnerships. "Our clients appreciate our focus on data quality, turn-around-time and responsiveness to meet their individual program needs."

The company has also seen significant uptake of their novel Orion platform including instruments and consumables for single-round highly multiplexed immunofluorescence staining and imaging of standard FFPE or fresh frozen tissue with additional benefits of industry-standard H&E and IHC modes. Combining speed and resolution, Orion enables comprehensive phenotypic profiling and characterization of tissue architecture, tumor heterogeneity, and immune response for whole slides in hours versus platforms that require multi-day workflows.

About RareCyte: RareCyte provides Precision Biology products and services for discovery, translational research, and clinical diagnostics. The Orion spatial biology platform enables same-day, 20 channel multiplexed tissue analysis. Our comprehensive liquid biopsy offering enables

CTC and other rare cell characterization and single-cell retrieval for molecular analysis, and CDx development.

For Research Use Only. Not for use in diagnostic procedures.

For more information about RareCyte, visit www.rarecyte.com.

Media Contact: <mailto:media@rarecyte.com>

KT Bohren-Cykler

RareCyte Inc.

+1 206-713-5299

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/559952943>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.